![]() |
|
|
Vol. 284, Issue 1, 1-9, 1998
Departments of
Pharmacology (S.A.V., J.H.W.) and
Psychology
(W.D.E., J.H.W.), The University of Michigan Medical School, Ann Arbor,
MI; and
CNS Neuropharmacology (D.P.T.), Bristol-Myers Squibb
Pharmaceutical Research Institute, Wallingford, CT
Pigeons were trained to discriminate intramuscular injections of 5.6 mg/kg BMY 14802, a drug that has relatively high affinity for
sigma binding sites, from saline in a two-key operant
procedure. Many compounds that displace sigma binding failed
to produce BMY 14802-like discriminative stimulus effects; these
included (+)-SKF 10,047, (+)3-PPP, DTG and MR 2035; the typical
antipsychotic haloperidol; the putative antipsychotics tiospirone,
cinuperone and rimcazole; and the uncompetitive NMDA antagonist
phencyclidine. In addition, MR 2035 and tiosperone failed to antagonize
the discriminative stimulus effects of BMY 14802. The selective
D2 antagonist eticlopride and the norepinephrine uptake
blocker and antidepressant desmethylimipramine also failed to evoke
substantial BMY 14802-appropriate responding. In contrast to
sigma ligands and other reference compounds, the 5-HT1A agonists buspirone, 8-OH-DPAT and spiroxatrine
dose-dependently produced BMY 14802-like discriminative stimulus
effects. The limited-efficacy 5-hydroxytryptamine (HT)1A
agonist NAN 190 did not produce BMY 14802-like discriminative effects;
however, it did competitively antagonize the stimulus effects of BMY
14802 and the BMY 14802-like stimulus effects of
(±)-8-hydroxy-2-(di-n-propylamino)tetralin. Other serotonergic
compounds failed to produce substantial BMY 14802-appropriate
responding; such as 5-HT1 agonist l-5-HTP;
5-HT1A/1B agonist RU24969; 5-HT1B/1C agonist
m-CPP; 5-HT1C/2 agonist quipazine; 5-HT1C/2 antagonists, metergoline and the atypical
antipsychotic clozapine; and 5-HT3 antagonist ondansetron.
Also, metergoline, ondansetron and pirenpirone failed to antagonize the
stimulus effects of BMY 14802. These results indicate that the
discriminative stimulus effects of BMY 14802 are serotonergically
mediated primarily by 5-HT1A receptors rather than by
sigma sites.